Effects of adjunctive pimavanserin and current antipsychotic treatment on QT interval prolongation in patients with schizophrenia

Effects of adjunctive pimavanserin and current antipsychotic treatment on QT interval prolongation in patients with schizophrenia

BackgroundPimavanserin prolongs the QT interval, with mean increases in corrected QT (QTc) of 5–8 ms, and is currently being investigated for the treatment of negative symptoms of schizophrenia.ObjectivesTo assess QT interval prolongation in 3 studies investigating once-daily pimavanserin as an adju...

Full description

Bibliographic Details
Main Authors:	Dragana Bugarski-Kirola, Rene Nunez, Ramzey Odetalla, I-Yuan Liu, Mary Ellen Turner
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-09-01
Series:	Frontiers in Psychiatry
Subjects:	pimavanserin schizophrenia QT interval antipsychotics adjunctive therapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fpsyt.2022.892199/full

Similar Items

Genetic Biomarkers of Antipsychotic-Induced Prolongation of the QT Interval in Patients with Schizophrenia
by: Elena E. Vaiman, et al.
Published: (2022-12-01)

Adherence to Background Antipsychotic and Pimavanserin in Patients with Schizophrenia: Post Hoc Analyses from the ENHANCE and ADVANCE Studies
by: Bugarski-Kirola D, et al.
Published: (2024-01-01)

The impact of adjunctive aripiprazole on QT interval: a 12-week open label study in patients on olanzapine, clozapine or risperidone
by: Pilunthanakul, Thanita, et al.
Published: (2023)

Title: Risk factors of prolonged corrected QT interval among patients with mental disorders
by: N. Smaoui, et al.
Published: (2021-04-01)

An analysis of the electrocardiogram QT interval
by: N.R. Koehler, et al.
Published: (2004-01-01)

The Effect of Aspirin on Schizophrenia; A Double Blind Placebo Controlled Study
by: Hamidreza Jamilian, Gevick Hacoupian
Published: (2017-12-01)

Pimavanserin: A Truly Effective Treatment for Parkinson’s Disease Psychosis? A Review of Interventions
by: Heim B, et al.
Published: (2023-05-01)

QT interval prolongation in Takotsubo syndrome: a frightening feature with no major prognostic impact
by: Ana Isabel Pinho, et al.
Published: (2023-12-01)

Risk of long-term care admissions among Medicare beneficiaries treated with pimavanserin or quetiapine for Parkinson’s disease psychosis in USA: a retrospective administrative claims database analysis
by: Krithika Rajagopalan, et al.
Published: (2023-12-01)

Assessment of corrected QT interval and QT dispersion in patients with uncomplicated metabolic syndrome
by: Amandeep Kaur, et al.
Published: (2023-01-01)

QT-prolongation as an indicator of complications in malaria
by: Sudhindra Rao Mananje, et al.
Published: (2017-01-01)

Pimavanserin and Parkinson’s Disease Psychosis: A Narrative Review
by: Jamir Pitton Rissardo, et al.
Published: (2022-09-01)

Prolongation of the QT interval under treatment with hydroxychloroquine in a patient with systemic lupus erythematosus: A case report
by: Ioan-Teodor Dragoi, et al.
Published: (2022-12-01)

The Relationship Between Antipsychotic Drug Use and Electrocardiography Parameters
by: Mehmet Emin Demİrkol, et al.
Published: (2019-12-01)

Specialty pharmacist integration into an outpatient neurology clinic improves pimavanserin access
by: Sabrina Livezey, PharmD, CSP, et al.
Published: (2021-05-01)

Microbial Transformation of Pimavanserin by <i>Cunninghamella blakesleeana</i> AS 3.970
by: Ming Song, et al.
Published: (2023-08-01)

Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis
by: Victor Abler, et al.
Published: (2022-10-01)

Detection of QT interval prolongation using Apple Watch electrocardiogram in children and adolescents with congenital long QT syndrome
by: Jennifer Yee-ming Li, et al.
Published: (2023-08-01)

QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy
by: Piccinelli Marco, et al.
Published: (2005-01-01)

QT Interval Dynamics and Cardiovascular Outcomes: A Cohort Study in an Integrated Health Care Delivery System
by: Neha Mantri, et al.
Published: (2021-10-01)

A prospective study on change of QTc interval with antipsychotic medications in patients of schizophrenia and related psychotic disorder
by: Shaswata Mandal, et al.
Published: (2024-04-01)

Pimavanserin treatment increases plasma brain-derived neurotrophic factor levels in rats
by: Ashutosh Tripathi, et al.
Published: (2023-08-01)

Prolonged QT Interval in SARS-CoV-2 Infection: Prevalence and Prognosis
by: Núria Farré, et al.
Published: (2020-08-01)

Association of QT interval-prolonging drugs with clinical trial eligibility in patients with advanced cancer
by: Elizabeth J. Rowe, et al.
Published: (2022-12-01)

QT interval analysis in type 2 diabetic patients
by: Kawthar H. Msayer
Published: (2011-01-01)

Bedaquiline Correlation to QT Interval Prolongation in DR-TB Patients
by: Vandu Primadana, et al.
Published: (2022-09-01)

Polypharmacy Management of Antipsychotics in Patients with Schizophrenia
by: Hiroyuki Kamei
Published: (2022-11-01)

KardiaMobile 6L for measuring QT interval in people having antipsychotic medication to inform early value assessment: a systematic review
by: Marie Westwood, et al.
Published: (2024-03-01)

Adjunctive antidepressive pharmacotherapy in schizophrenia patients
by: M. Zink
Published: (2021-04-01)

Methods of Assessment and Clinical Relevance of QT Dynamics
by: Beata Sredniawa, et al.
Published: (2005-07-01)

Energy Drinks: Another Cause of QT Prolongation?
by: Michael D. Winniford
Published: (2019-06-01)

Serial electrocardiogram recordings revealed a high prevalence of QT interval prolongation in patients with tuberculosis receiving fluoroquinolones
by: Ke-Shiuan Ju, et al.
Published: (2023-12-01)

Syncope with QT‐interval prolongation and T‐wave inversion in anterior and inferior leads: Foreboder of a life‐threatening condition?
by: Jing‐Xiu Li, et al.
Published: (2023-01-01)

Atypical antipsychotics in the treatment of schizophrenia
by: Swiss Medical Weekly
Published: (2003-02-01)

Evaluation of Tpeak–Tend and QT intervals in Chagas’ Disease, Chronic Phase and Normal Electrocardiogram
by: Abilio Augusto Fragata Filho, et al.
Published: (2020-04-01)

Smart devices to measure and monitor QT intervals
by: Leendert J. Hoek, et al.
Published: (2023-11-01)

Effectiveness of antipsychotics in schizophrenia with comorbid substance use disorder
by: M. Lähteenvuo, et al.
Published: (2021-04-01)

Drug-induced QT interval prolongation in cancer patients
by: Torben K. Becker, et al.
Published: (2011-12-01)

Tomenendalova J: How to approach the QT interval in dogs - the state of the heart: a review
by: C.F. Agudelo, et al.
Published: (2011-01-01)

Approach to the management of psychosis in Parkinson’s disease
by: Abhishek Lenka, et al.
Published: (2019-01-01)